1. Home
  2. CAAP vs FOLD Comparison

CAAP vs FOLD Comparison

Compare CAAP & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Corporacion America Airports SA

CAAP

Corporacion America Airports SA

HOLD

Current Price

$26.01

Market Cap

4.2B

ML Signal

HOLD

Logo Amicus Therapeutics Inc.

FOLD

Amicus Therapeutics Inc.

HOLD

Current Price

$14.33

Market Cap

4.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CAAP
FOLD
Founded
1998
2002
Country
Luxembourg
United States
Employees
N/A
N/A
Industry
Aerospace
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.2B
4.4B
IPO Year
2018
2007

Fundamental Metrics

Financial Performance
Metric
CAAP
FOLD
Price
$26.01
$14.33
Analyst Decision
Strong Buy
Buy
Analyst Count
2
9
Target Price
$25.85
$27.56
AVG Volume (30 Days)
138.6K
20.9M
Earning Date
11-24-2025
02-18-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
1.09
N/A
Revenue
$1,872,934,000.00
$598,704,000.00
Revenue This Year
$5.19
$21.49
Revenue Next Year
$7.63
$18.46
P/E Ratio
$23.84
N/A
Revenue Growth
25.19
21.28
52 Week Low
$15.01
$5.51
52 Week High
$27.76
$14.38

Technical Indicators

Market Signals
Indicator
CAAP
FOLD
Relative Strength Index (RSI) 52.19 86.54
Support Level $25.16 $14.30
Resistance Level $27.31 $14.38
Average True Range (ATR) 0.78 0.05
MACD -0.20 -0.15
Stochastic Oscillator 36.15 68.69

Price Performance

Historical Comparison
CAAP
FOLD

About CAAP Corporacion America Airports SA

Corporacion America Airports SA acquires, develops, and operates airport concessions. Its operating segments are geographically divided into Argentina, Italy, Brazil, Uruguay, Ecuador, and Armenia. The company generates a majority of its revenue from the Argentina segment. The firm's revenue is categorized into Aeronautical Revenue, Non-Aeronautical Revenue, Commercial Revenue, Construction Service Revenue, and Other Revenue.

About FOLD Amicus Therapeutics Inc.

Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.

Share on Social Networks: